Centre for Synaptic Plasticity, School of Physiology, Pharmacology and Neuroscience, University of Bristol, Biomedical Sciences Building, University Walk, Bristol, BS8 1TD, UK.
Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, 68198-5800, USA.
Eur J Med Chem. 2019 Feb 15;164:471-498. doi: 10.1016/j.ejmech.2018.12.054. Epub 2018 Dec 28.
The N-methyl-D-aspartate receptor (NMDAR), a ligand-gated ion channel activated by L-glutamate and glycine, plays a major role in the synaptic plasticity underlying learning and memory. NMDARs are involved in neurodegenerative disorders such as Alzheimer's and Parkinson's disease and NMDAR hypofunction is implicated in schizophrenia. Herein we describe structure-activity relationship (SAR) studies on 2-naphthoic acid derivatives to investigate structural requirements for positive and negative allosteric modulation of NMDARs. These studies identified compounds such as UBP684 (14b), which act as pan potentiators by enhancing NMDAR currents in diheteromeric NMDAR tetramers containing GluN1 and GluN2A-D subunits. 14b and derivatives thereof are useful tools to study synaptic function and have potential as leads for the development of drugs to treat schizophrenia and disorders that lead to a loss of cognitive function. In addition, SAR studies have identified a series of styryl substituted compounds with partial NAM activity and a preference for inhibition of GluN2D versus the other GluN2 subunits. In particular, the 3-and 2-nitrostyryl derivatives UBP783 (79i) and UBP792 (79h) had ICs of 1.4 μM and 2.9 μM, respectively, for inhibition of GluN2D but showed only 70-80% maximal inhibition. GluN2D has been shown to play a role in excessive pain transmission due to nerve injury and potentially in neurodegenerative disorders. Partial GluN2D inhibitors may be leads for the development of drugs to treat these disorders without the adverse effects observed with full NMDAR antagonists.
N-甲基-D-天冬氨酸受体(NMDAR)是一种配体门控离子通道,由 L-谷氨酸和甘氨酸激活,在学习和记忆所涉及的突触可塑性中发挥主要作用。NMDAR 参与神经退行性疾病,如阿尔茨海默病和帕金森病,并且 NMDAR 功能低下与精神分裂症有关。在此,我们描述了 2-萘甲酸衍生物的构效关系(SAR)研究,以研究对 NMDAR 的正变构和负变构调节的结构要求。这些研究确定了诸如 UBP684(14b)之类的化合物,它们通过增强包含 GluN1 和 GluN2A-D 亚基的二杂合 NMDAR 四聚体中的 NMDAR 电流而作为泛增强剂发挥作用。14b 及其衍生物是研究突触功能的有用工具,并且有可能作为治疗精神分裂症和导致认知功能丧失的疾病的药物开发的先导化合物。此外,SAR 研究还确定了一系列具有部分 NAM 活性的苯乙烯取代化合物,并且对抑制 GluN2D 相对于其他 GluN2 亚基具有偏好。特别是,3-和 2-硝基苯乙烯衍生物 UBP783(79i)和 UBP792(79h)对 GluN2D 的抑制 IC50 分别为 1.4 μM 和 2.9 μM,但仅表现出 70-80%的最大抑制。已经表明 GluN2D 在神经损伤引起的过度疼痛传递中以及在神经退行性疾病中发挥作用。部分 GluN2D 抑制剂可能是开发治疗这些疾病的药物的先导化合物,而没有与完全 NMDAR 拮抗剂观察到的不良反应。